【摘要】：目的觀察鹽酸多奈哌齊片聯(lián)合司來吉蘭片治療帕金森病的臨床療效和安全性。方法將92例帕金森病患者隨機(jī)分為對(duì)照組46例和試驗(yàn)組46例。對(duì)照組予以司來吉蘭片每次5 mg,bid,口服;試驗(yàn)組在對(duì)照組治療的基礎(chǔ)上,予以鹽酸多奈哌齊片每次5 mg,bid,口服。2組患者均治療2個(gè)月。比較2組患者的臨床療效、帕金森病評(píng)分量表(UPDRS)、蒙特利爾認(rèn)知評(píng)估量表(MoCA)和簡(jiǎn)易精神狀態(tài)量表(MMSE)評(píng)分、Barthel指數(shù)、超氧化物歧化酶(SOD)、丙二醛(MDA)、谷胱甘肽(GSH),以及藥物不良反應(yīng)的發(fā)生情況。結(jié)果治療后,試驗(yàn)組和對(duì)照組的總有效率分別為95.65%(44/46例)和76.09%(35/46例),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。治療后,試驗(yàn)組和對(duì)照組的UPDRS評(píng)分分別為(47.03±7.21),(61.67±7.28)分;MoCA評(píng)分分別為(27.04±1.97),(20.67±2.15)分;MMSE評(píng)分分別為(25.63±3.57),(22.25±3.64)分;Barthel指數(shù)分別為(79.29±9.15),(68.43±9.32)分;SOD分別為(117.54±16.14),(98.43±15.12)kU·L~(-1);MDA分別為(5.13±1.83),(5.96±2.14)μmol·L~(-1);GSH分別為(47.66±8.57),(35.27±8.35)μmol·L~(-1),差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。2組患者的藥物不良反應(yīng)以口干、睡眠障礙、惡心、腹瀉、食欲減退為主,試驗(yàn)組和對(duì)照組的藥物不良反應(yīng)發(fā)生率分別為32.61%和23.91%,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論鹽酸多奈哌齊片聯(lián)合司來吉蘭片治療帕金森病的臨床療效顯著,其能顯著提高患者的認(rèn)知功能、日常生活能力和精神狀態(tài),減輕氧化應(yīng)激水平,且不增加藥物不良反應(yīng)的發(fā)生率。
[Abstract]:Objective to observe the clinical efficacy and safety of Donepezil Hydrochloride (Donepezil Hydrochloride) combined with selegilan tablets in the treatment of Parkinson's disease. Methods 92 patients with Parkinson's disease were randomly divided into control group (n = 46) and experimental group (n = 46). In the control group, 5 mg bid was given each time, while in the experimental group, the dosage of Donepezil hydrochloride was 5 mg bid each time, and the patients in the 2 groups were treated for 2 months on the basis of the treatment in the control group. To compare the clinical efficacy of the two groups, (UPDRS), Montreal Cognitive Assessment scale (MoCA) and Mini-Mental State scale (MMSE) were used to evaluate the clinical efficacy of the two groups. Superoxide dismutase (SOD), malondialdehyde (MDA), glutathione (GSH), and adverse drug reactions. Results after treatment, the total effective rates of the experimental group and the control group were 95.65% (44 / 46 cases) and 76.09% (35 / 46 cases), respectively. The difference was statistically significant (P0.05). After treatment, 璇曢獙緇勫拰瀵圭収緇勭殑UPDRS璇勫垎鍒嗗埆涓，

本文編號(hào)：2156646